Literature DB >> 15196070

Successful simultaneous islet-kidney transplantation using a steroid-free immunosuppression: two-year follow-up.

Roger Lehmann1, Markus Weber, Peter Berthold, Richard Züllig, Thomas Pfammatter, Wolfgang Moritz, Kathrin Mädler, Marc Donath, Patrice Ambühl, Nicolas Demartines, Pierr-Alain Clavien And, Giatgen Andreia Spinas.   

Abstract

We report on the feasibility of a glucocorticoid-free immunosuppression (sirolimus, low-dose tacrolimus, and daclizumab) in simultaneous islet-kidney transplantation in nine patients with type 1 diabetes. There was one renal primary nonfunction. Renal function (n = 8) as assessed by creatinine and creatinine clearance over time was 103 +/- 6 micromol/L and 64 +/- 6 mL/min/1.73 m(2), respectively. Five out of six patients with >or= 2 islet transplantations became insulin independent. The mean HbA(1c) during the follow-up period for all patients after transplantation is 6.2 +/- 0.9% as compared with 8.7 +/- 1.9% prior to transplant. These results in patients with a median follow-up of 2.3 years suggest that kidney transplantation under a glucocorticoid-free immunosuppression is feasible, and that the rate of insulin independence of 80% can be achieved not only in patients with no or minimal diabetes complications, but also in patients with more advanced late complications and in conjunction with kidney transplantation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15196070     DOI: 10.1111/j.1600-6143.2004.00468.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  10 in total

Review 1.  Islet transplantation: current status and future directions.

Authors:  Betul Hatipoglu; Enrico Benedetti; José Oberholzer
Journal:  Curr Diab Rep       Date:  2005-08       Impact factor: 4.810

2.  Simultaneous islet-kidney vs pancreas-kidney transplantation in type 1 diabetes mellitus: a 5 year single centre follow-up.

Authors:  P A Gerber; V Pavlicek; N Demartines; R Zuellig; T Pfammatter; R Wüthrich; M Weber; G A Spinas; R Lehmann
Journal:  Diabetologia       Date:  2007-11-01       Impact factor: 10.122

3.  Nitric oxide contributes to cytokine-induced apoptosis in pancreatic beta cells via potentiation of JNK activity and inhibition of Akt.

Authors:  J Størling; J Binzer; A K Andersson; R A Züllig; M Tonnesen; R Lehmann; G A Spinas; S Sandler; N Billestrup; T Mandrup-Poulsen
Journal:  Diabetologia       Date:  2005-08-25       Impact factor: 10.122

Review 4.  Pancreatic Islet Transplantation in Humans: Recent Progress and Future Directions.

Authors:  Michael R Rickels; R Paul Robertson
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

Review 5.  Use of sirolimus in solid organ transplantation.

Authors:  Joshua J Augustine; Kenneth A Bodziak; Donald E Hricik
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 6.  Progress and challenges in macroencapsulation approaches for type 1 diabetes (T1D) treatment: Cells, biomaterials, and devices.

Authors:  Shang Song; Shuvo Roy
Journal:  Biotechnol Bioeng       Date:  2016-01-04       Impact factor: 4.530

7.  Immunosuppression With CD40 Costimulatory Blockade Plus Rapamycin for Simultaneous Islet-Kidney Transplantation in Nonhuman Primates.

Authors:  T Oura; K Hotta; J Lei; J Markmann; I Rosales; A Dehnadi; K Kawai; D Ndishabandi; R-N Smith; A B Cosimi; T Kawai
Journal:  Am J Transplant       Date:  2016-09-06       Impact factor: 8.086

Review 8.  Current status of islet cell transplantation.

Authors:  Hirohito Ichii; Camillo Ricordi
Journal:  J Hepatobiliary Pancreat Surg       Date:  2008-12-26

9.  Simultaneous islet and kidney transplantation in seven patients with type 1 diabetes and end-stage renal disease using a glucocorticoid-free immunosuppressive regimen with alemtuzumab induction.

Authors:  Jianming Tan; Shunliang Yang; Jinquan Cai; Junqi Guo; Lianghu Huang; Zhixian Wu; Jin Chen; Lianming Liao
Journal:  Diabetes       Date:  2008-07-15       Impact factor: 9.461

Review 10.  Design Considerations for Macroencapsulation Devices for Stem Cell Derived Islets for the Treatment of Type 1 Diabetes.

Authors:  Debkalpa Goswami; Daniel A Domingo-Lopez; Niamh A Ward; Jeffrey R Millman; Garry P Duffy; Eimear B Dolan; Ellen T Roche
Journal:  Adv Sci (Weinh)       Date:  2021-06-21       Impact factor: 16.806

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.